SCHEDULE: Cormorant Asset Management Boosts BioAge Stake

Cormorant Asset Management, LP and Bihua Chen report a 5.97% beneficial ownership stake in BioAge Labs, Inc., holding 2,140,605 shares.

Summary

• Cormorant Asset Management, LP and Bihua Chen collectively hold 2,140,605 shares of BioAge Labs, Inc. Common Stock.
• This ownership represents 5.97% of the outstanding Common Stock of BioAge Labs, Inc.
• The percentage is calculated based on 35,850,037 shares outstanding as of August 1, 2025, as reported in the Issuer's Quarterly Report on Form 10-Q for the period ended June 30, 2025.
• Cormorant Asset Management, LP acts as an investment adviser to certain funds (the "Cormorant Funds"), which directly hold the shares.
• Bihua Chen is also a reporting person with respect to the shares held by the Cormorant Funds.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of the issuer.

Sentiment

Score: 7

Explanation: The filing indicates a significant beneficial ownership stake by a reputable institutional investor, which is generally viewed as a positive signal of confidence in the issuer by the market.

Positives

• The disclosure of a significant beneficial ownership stake by Cormorant Asset Management, a specialized investment firm, may signal institutional confidence in BioAge Labs, Inc.

Risks

• The filing does not detail specific operational or financial risks related to BioAge Labs, Inc. It is a disclosure of beneficial ownership.
• The reporting persons certify that the shares were not acquired for the purpose of changing or influencing the control of the issuer, mitigating potential risks associated with activist investor intervention.

Future Outlook

This filing is a beneficial ownership report and does not contain forward-looking statements or guidance from BioAge Labs, Inc. or the reporting persons regarding the issuer's future performance.

Industry Context

This filing indicates continued institutional investor interest in the biotechnology sector, with Cormorant Asset Management, a firm known for its focus on healthcare and life sciences, taking a significant stake in BioAge Labs, Inc. This aligns with broader trends of specialized funds investing in promising biotech companies.

Stakeholder Impact

• Shareholders: Increased institutional ownership may lead to greater market confidence and potentially influence trading liquidity.

Key Dates

Keywords

BioAge Labs, Cormorant Asset Management, Bihua Chen, Beneficial Ownership, Schedule 13G, Biotech, Investment, Institutional Investor, Common Stock